By Karen Roman
Oncolytics Biotech Inc. (Nasdaq: ONCY) said it has new data showing the use of pelareorep in metastatic colorectal cancer has a 19.5-month median duration of response compared to the 4–6 months historical benchmarks.
The company is enrolling patients for its Phase 2 study to evaluate pelareorep combined with FOLFIRI and bevacizumab, and is in conversations with the FDA for a potential accelerated approval pathway, it stated.
“We believe these data demonstrate a compelling durability signal for pelareorep in colorectal cancer,” said Jared Kelly, Oncolytics CEO. “We believe these results support a path toward accelerated approval in second-line RAS-mutant MSS metastatic colorectal cancer.”
READ MORE
Final Agenda and Registration – 2nd Princeton CorpGov Forum: Endowments, Activism and Entertainment
Never Miss our Weekly Highlights HERE
Contact:
Editor@IPO-Edge.com
Click HERE to follow us on LinkedIn
